CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score -0.6: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
407.99MUSDvs all stocks (USD)
Revenue (TTM)
34.86MUSDvs all stocks (USD)
Profit Margin
-297.76%vs Biotechnology peers
Beta
2.91xvs all stocks
52-Week Change
62.55%vs all stocks
Market Capitalization
407.99MUSDvs all stocks (USD)
Enterprise Value
242.93MUSDvs all stocks (USD)
Forward P/E
-3.44xvs Biotechnology peers
Price to Sales (TTM)
11.35xvs Biotechnology peers
Price to Book (MRQ)
1.59xvs Biotechnology peers
Enterprise to Revenue
6.97xvs Biotechnology peers
Enterprise to EBITDA
-2.40xvs Biotechnology peers
Profit Margin
-297.76%vs Biotechnology peers
Operating Margin
-451.64%vs Biotechnology peers
Return on Assets (TTM)
-19.88%vs Biotechnology peers
Return on Equity (TTM)
-48.35%vs Biotechnology peers
Revenue (TTM)
34.86MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3600USDUpdated Jul 18, 2026Quarterly Revenue Growth
-15.00%vs Biotechnology peers
Gross Profit (TTM)
27.31MUSDvs all stocks (USD)
EBITDA (TTM)
-101.20MUSDvs all stocks (USD)
Net Income (TTM)
-103.80MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-15.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-95.35MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-53.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
35.95MUSDFY2025 · Dec 31, 2025Operating Income
-104.49MUSDvs all stocks (USD)
Pre-tax Income
-104.87MUSDFY2025 · Dec 31, 2025Income Tax Expense
121.00KUSDFY2025 · Dec 31, 2025Net Income
-104.99MUSDFY2025 · Dec 31, 2025EBIT
-104.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-91.80MUSDFY2025 · Dec 31, 2025Research & Development
104.24MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
36.20MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.35MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-104.99MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-108.21MUSDFY2025 · Dec 31, 2025Free Cash Flow
-108.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.05MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-104.99MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.96MUSDFY2025 · Dec 31, 2025Stock-based Compensation
19.10MUSDFY2025 · Dec 31, 2025Other Non-cash Items
99.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
701.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-468.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-24.61MUSDFY2025 · Dec 31, 2025Capital Expenditures
-607.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-227.07MUSDFY2025 · Dec 31, 2025Sale of Investments
219.08MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-8.60MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-193.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
274.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
126.29MUSDFY2025 · Dec 31, 2025Shares Outstanding
104.04MSharesUpdated Jul 18, 2026Float Shares
83.71MSharesUpdated Jul 18, 2026Shares Short
25.00MSharesUpdated Jul 18, 2026Short Ratio
7.08daysvs all stocks
Short % of Shares Outstanding
22.76%vs all stocks
% Held by Insiders
0.93%vs all stocks
% Held by Institutions
85.32%vs all stocks
Total Cash (MRQ)
235.67MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.13USDUpdated Jul 18, 2026Total Debt (MRQ)
58.45MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2495xvs Biotechnology peers
Current Ratio (MRQ)
9.01xvs Biotechnology peers
Book Value per Share (MRQ)
2.25USDUpdated Jul 18, 2026Total Assets
359.07MUSDvs all stocks (USD)
Total Current Assets
258.11MUSDFY2025 · Dec 31, 2025Total Liabilities
102.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
100.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
69.46MUSDFY2025 · Dec 31, 2025Total Current Liabilities
33.03MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
74.60MUSDFY2025 · Dec 31, 2025Other Short-term Investments
173.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.40MUSDFY2025 · Dec 31, 2025Accounts Payable
858.00KUSDFY2025 · Dec 31, 2025Short-term Debt
6.37MUSDFY2025 · Dec 31, 2025Deferred Revenue
12.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.40MUSDFY2025 · Dec 31, 2025Long-term Debt
53.62MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-738.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
256.59MUSDvs all stocks (USD)
52-Week Low
1.69USDUpdated Jul 18, 202652-Week High
5.17USDUpdated Jul 18, 202652-Week Change
62.55%vs all stocks
Beta
2.91xvs all stocks
50-Day MA
3.81USDUpdated Jul 18, 2026200-Day MA
2.78USDUpdated Jul 18, 2026Avg 10-Day Volume
3.46MSharesUpdated Jul 18, 2026Avg 30-Day Volume
3.54MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.10USDUpdated Jul 18, 2026Other Income / Expense
-10.73MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 9.01Altman Z-Score: -0.60
Financial Health
Altman Z-Score -0.6: distress zoneCritical
Altman Z-Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crescent Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Century Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Bioeasy Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhuzhou Hongda Electronics Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Standard Biotools Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Guangdong Guangzhou Daily Media Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedMulti-Year Debt Decrease With Cash Near Total Debt And Equity